SCHEMBL5136516

SCHEMBL5136516

CCCCN(Cc1ccccc1CO)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 3/20 0.42
HDAC1 Q13547 1/20 0.40
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 4/20 0.39
CYP3A4 P08684 3/20 0.39
NR1H3 Q13133 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
PDE4B Q07343 3/20 0.35
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5074963 0.90 C5AR1 (0.43) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL5137095 0.89 C5AR1 (0.45) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL650694 0.88 TSHR (0.51) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL5135923 0.88 C5AR1 (0.43) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL5135312 0.88 C5AR1 (0.46) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL5134961 0.88 C5AR1 (0.43) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL5137577 0.88 C5AR1 (0.43) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL5135633 0.86 C5AR1 (0.42) C5AR1TSHRHDAC1ALDH1A1KDM4E
SCHEMBL649161 0.86 C5AR1 (0.47) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5069962 0.86 BCHE (0.45) C5AR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed